Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Hu, Chaoquan ^a,b   Huang, Limin ^c   Gest, Caroline ^c   Xi, Xiaodong ^d   Janin, Anne ^a,b,e   Soria, Claudine ^c   Li, Hong ^c   Lu, He ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

Breast cancer; Gene expression regulation; MAPK ERK pathway; PI3K Akt pathway; Pro coagulation activity; Tissue factor; Tumor invasiveness

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOAGULANT; PROTEIN KINASE B; SMALL INTERFERING RNA; THROMBOPLASTIN; WORTMANNIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INVASION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OVARY CANCER; PLASMID; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

BLOOD COAGULATION; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 84860184295     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-16     Document Type: Article

References (33)

1. Role of tissue factor in embryonic blood vessel development. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, Nature 1996 383 73 75 10.1038/383073a0 8779717 (Pubitemid 26296462)
2. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Belting M, Ahamed J, Ruf W, Arterioscler Thromb Vasc Biol 2005 25 1545 1550 10.1161/01.ATV.0000171155.05809.bf 15905465 (Pubitemid 41098920)
3. The role of tissue factor and factor VIIa in hemostasis. Mackman N, Anesth Analg 2009 108 1447 1452 10.1213/ane.0b013e31819bceb1 19372318
4. The relationship between tissue factor and cancer progression: insights from bench and bedside. Van den Berg YW, Osanto S, Reitsma PH, Versteeg HH, Blood 2012 119 924 932 10.1182/blood-2011-06-317685 22065595
5. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor B, and Egr-1. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schönbeck U, J Biol Chem 2002 277 25032 25039 10.1074/jbc.M204003200 11978801 (Pubitemid 34951807)
6. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, Lupu F, Lind SE, Ding WQ, J Biol Chem 2011 286 1429 1435 10.1074/jbc.M110.146530 21059650
7. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW, Blood 2005 105 1734 41 10.1182/blood-2004-05-2042 15494427 (Pubitemid 40223697)
8. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, Van Meir EG, Mackman N, Brat DJ, Cancer Res 2009 269 2540 2549
9. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S, Mol Carcinog 1998 21 234 243 10.1002/(SICI)1098- 2744(199804)21:4<234::AID-MC2>3.0.CO;2-K 9585253 (Pubitemid 28208744)
10. Lipopolysaccharide activation of the ERK1-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Guha M, OConnell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N, Blood 2001 98 1429 1439 10.1182/blood.V98.5.1429 11520792
11. Tissue factor in cardiovascular diseases:molecular mechanisms and clinical implications. Steffel J, Lüscher TF, Tanner FC, Circulation 2006 113 722 731 10.1161/CIRCULATIONAHA.105.567297 16461845
12. Alternatively spliced tissue factor. A crippled protein in coagulation ora key player in non haemostatic processes. van den Berg YW, Versteeg HH, Hamostaseologie 2010 30 144 149 20680231
13. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y, Nat Med 2003 4 458 462 (Pubitemid 36460081)
14. Alternatively spliced tissue factor: discovery, insights, clinical implications. Srinivasan R, Bogdanov VY, Front Biosci 2011 17 3061 3071 21622222
15. Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Eisenreich A, Malz R, Pepke W, Ayral Y, Poller W, Schultheiss HP, Rauch U, Circ J 2009 73 1746 1752 10.1253/circj.CJ-99-0225 19597299
16. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY, Versteeg HH, Proc Natl Acad Sci U S A 2009 106 19497 19502 10.1073/pnas.0905325106 19875693
17. Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Hobbs JE, Zakarija A, Cundiff DL, Doll JA, Hymen E, Cornwell M, Crawford SE, Liu N, Signaevsky M, Soff GA, Thromb Res 2007 120 13 S21 18023707
18. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U, Oncol Rep 2008 20 123 128 18575726
19. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T, Br J Cancer 2000 83 164 170 10901365 (Pubitemid 30411712)
20. PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. Yan J, Wang K, Dong L, Liu H, Chen W, Xi W, Ding Q, Kieffer N, Caen JP, Chen S, Chen Z, Xi X, Proc Natl Acad Sci USA 2010 107 3716 3721 10.1073/pnas.0915006107 20133705
21. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. Szotowski B, Goldin-Lang P, Antoniak S, Bogdanov VY, Pathirana D, Pauschinger M, Dörner A, Kuehl U, Coupland S, Nemerson Y, Hummel M, Poller W, Hetzer R, Schultheiss HP, Rauch U, J Am Coll Cardiol 2005 45 1081 9 10.1016/j.jacc.2004.12.061 15808768 (Pubitemid 40432443)
22. Differential roles of ERKand Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y, Oncogene 2010 29 4947 4958 10.1038/onc.2010.240 20562913
23. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA, Oncotarget 2011 2 135 164 21411864
24. PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N, Arterioscler Thromb Vasc Biol 2004 24 1963 1969 10.1161/01.ATV.0000143096.15099.ce 15319270 (Pubitemid 39350320)
25. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Guha M, OConnell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N, Blood 2001 8 1429 1439
26. The P2Y2 nucleotide receptor mediates tissue factor expression in human coronary artery endothelial cells. Ding L, Ma W, Littmann T, Camp R, Shen J, J Biol Chem 2011 286 27027 27038 10.1074/jbc.M111.235176 21652710
27. Down-regulation of the PI3-kinase/Akt pathway by ERKMAP kinase in growth factor signaling. Hayashi H, Tsuchiya Y, Nakayama K, Satoh T, Nishida E, Genes Cells 2008 13 941 947 10.1111/j.1365-2443.2008.01218.x 18691227
28. Targeting cancer with small-molecular-weight kinase inhibitors. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G, Methods Mol Biol 2012 795 1 34 10.1007/978-1-61779-337-0-1 21960212
29. Growth factor/growth factor receptor loops in autocrine growth regulation of human prostate cancer DU145 cells. Ligza J, Ligza J, Klein A, Acta Biochim Pol 2011 58 391 396 21887406
30. Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells. Popova T, Espina V, Bailey C, Liotta L, Petricoin E, Popov S, FEMS Immunol Med Microbiol 2009 56 129 142 10.1111/j.1574-695X.2009.00558.x 19416348
31. Antagonistic roles of four SR proteins in the biosynthesis of alternatively spliced tissue factor transcripts in monocytic cells. Chandradas S, Deikus G, Tardos JG, Bogdanov V, J Leukoc Biol 2010 87 147 152 10.1189/jlb.0409252 19843576
32. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolainc PM, Terrian DM, Franklin RA, DAssoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M, Advan Enzyme Regul 2006 46 249 279 10.1016/j.advenzreg.2006.01.004 (Pubitemid 44301348)
33. EGFR signaling and drug discovery. Lurje G, Lenz HJ, Oncology 2009 77 400 410 10.1159/000279388 20130423